H.C. Wainwright Reiterates a Buy Rating on Nuvation Bio (NUVB)

Nuvation Bio Inc. (NYSE:NUVB) is one of the top strong buy stocks under $5 to buy now. In a report released on August 8, Robert Burns from H.C. Wainwright reiterated a Buy rating on Nuvation Bio Inc. (NYSE:NUVB) with a price target of $10.00.

Is Nuvation Bio Inc. (NUVB) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?

A close-up of researchers, carefully studying a biopharmaceutical compound in a laboratory.

Similarly, in a report released on August 7, Leonid Timashev from RBC Capital reiterated a Buy rating on Nuvation Bio Inc. (NYSE:NUVB) and set a price target of $7.00.

The same day, David Nierengarten from Wedbush also maintained a Buy rating on Nuvation Bio Inc. (NYSE:NUVB) with a price target of $6.00. The stock’s median price target of $2.90 implies an upside of 141.38% from current levels.

Nuvation Bio (NYSE:NUVB) is a biopharmaceutical company that develops therapeutic and differentiated candidates to tackle the gaps in oncology.

While we acknowledge the potential of NUVB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NUVB and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.